ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO085

Effects of Cardiovascular Outcomes of Sacubitril-Valsartan in Patients With AKI

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology‚ Risk Factors‚ and Prevention

Authors

  • Choi, Hoon Young, Yonsei University College of Medicine, Seodaemun-gu, Korea (the Republic of)
  • Oh, Donghwan, Yonsei University College of Medicine, Seodaemun-gu, Korea (the Republic of)
  • Yang, Eunji, Yonsei University College of Medicine, Seodaemun-gu, Korea (the Republic of)
  • Jhee, Jong Hyun, Yonsei University College of Medicine, Seodaemun-gu, Korea (the Republic of)
  • Park, Hyeong cheon, Yonsei University College of Medicine, Seodaemun-gu, Korea (the Republic of)
Background

Sacubitril-valsartan reduced the risk of cardiovascular (CV) mortality among patients with heart failure with reduced ejection fraction (HFrEF). However, it is still unclear a long term protective effect on cardiac function in HFrEF patients with acute kidney injury (AKI). This study aimed to investigate the association between long term effects of CV protection and AKI treated by sacubitril-valsartan.

Methods

Data were retrieved from the Severance Open Big Data Portal. Patients under Sacubitril-valsartan or valsartan medication after diagnosis of heart failure between May 2015 and June 2021 (N = 782). A total of 295 patients with HFrEF treated by sacubitril-valsartan or valsartan were enrolled. The participants were divided into each group to study the effect of sacubitril-valsartan in patients taking valsartan as a control group. The ratio (△ Ejection Fraction(EF)/△ estimated glomerular filtration rate(eGFR)) was used to analyze the association between CV and renal outcomes during the study period.

Results

The total of 295 patients with HFrEF and the rate of patient with AKI accounted for 9.5% of the total. Baseline characteristics show that the mean age of the HFrEF patients with AKI was 76.1 ± 9.4 years, and 65.5% were male. The mean level of eGFR were 41.5 ± 23.4 in sacubitril-valsartan group and 64.9 ± 23.1 mL/min/1.73m2 in valsartan group. The mean level of EF (%) were 28.0 ± 6.4 in sacubitril-valsartan group and 37.5 ± 12.6 in valsartan group. When the association between renal outcome and cardiovascular outcome was analyzed by independent two sample t-test, the sacubitril-valsartan group improved cardiovascular outcomes compared to valsartan group (Difference value 11.2 ± 13.1% in sacubitril-valsartan group and -0.6 ± 11.1% in valsartan group, P= 0.03).

Conclusion

The present study demonstrated that HFrEF patients treated with sacubitril-valsartan had a significant improved cardiovascular outcome even if AKI.